Study of Remibrutinib for chronic hives
Part of Immune system & allergy, Skin clinical trials.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- A doctor has diagnosed you with chronic spontaneous urticaria (CSU).
- Your doctor has prescribed remibrutinib or dupilumab, and you plan to start taking it soon.
- You have access to a device with internet (like a smartphone or computer).
- You can read and understand English.
- You haven't used oral steroids (like prednisone) in the 14 days before starting the study medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
This study observes how remibrutinib (a newer medication) works for chronic hives (CSU) when prescribed in routine clinical practice in Germany. Remibrutinib is used when standard allergy medications don't work well enough. The study tracks your symptoms and treatment over 24 months to understand how well it helps real patients.
This program offers remibrutinib, an experimental oral medication, to adults with chronic spontaneous urticaria (long-lasting hives without a known trigger) that hasn't improved with standard antihistamines or omalizumab. It aims to see if this drug can reduce symptoms when other options haven't worked.
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.